Current Atherosclerosis Reports, Journal Year: 2024, Volume and Issue: 27(1)
Published: Nov. 25, 2024
Language: Английский
American Journal of Preventive Cardiology, Journal Year: 2024, Volume and Issue: 17, P. 100639 - 100639
Published: Feb. 15, 2024
As the global population ages and cardiovascular risk factors rise, we can expect a continued increase in atherosclerotic disease. Low-density lipoprotein cholesterol (LDL-C) reduction is cornerstone of with strong, causal evidence indicating that greatest benefit derived from early large decreases LDL-C. Despite adoption statins as backbone lipid-therapy regimens, numerous studies registry analyses reveal our collective inability to achieve LDL-C goals high-risk patients. Combination therapy ezetimibe has been shown result statistically significant level, atheroma volume, adverse event rates. A major barrier implementing an upfront combination approach perceived side effects therapeutic agents although multiple show patient-physician relationship could overcome this issue. Novel such PCSK-9 inhibitors, bempedoic acid, inclisiran have potential similar outcomes additional research needed regarding cost effectiveness these approaches. hurdles, there role for newer disease course patients those markedly elevated >190 mg/dL FH. The implementation therapy, especially patients, will decrease clinical inertia while allowing earlier consideration newer, effective burden.
Language: Английский
Citations
3
Cureus, Journal Year: 2024, Volume and Issue: unknown
Published: March 10, 2024
This meta-analysis aimed to compare the effectiveness of high statin monotherapy and a combination ezetimibe prevent cardiovascular outcomes in patients with acute coronary syndrome (ACS). The study was conducted according Preferred Reporting Items for Systematic Reviews Meta-Analyses (PRISMA) guidelines. We comprehensive searches across online databases, including MEDLINE/ PubMed, EMBASE, Web Science, find relevant articles from databases' inception 10 Feb 2024. Outcomes assessed included major events (MACE), all-cause mortality, stroke, myocardial infarction, unplanned revascularization. Data analysis utilizing RevMan Version 5.3.1. comparison between two groups involved calculation risk ratios (RR) accompanied by 95% confidence intervals (CI) using either random or fixed-effect model. Five studies were this meta-analysis, encompassing 48,668 patients. pooled showed that mortality higher receiving monotherapy. However, no significant differences MACE, revascularization reported. While acknowledging limitations, lack randomized controlled trials dominance one analysis, these findings underscore importance further research clarify comparative treatment modalities preventing ACS
Language: Английский
Citations
3
European Journal of Preventive Cardiology, Journal Year: 2024, Volume and Issue: 31(15), P. 1850 - 1860
Published: Aug. 5, 2024
Abstract Aims Women are less likely to receive lipid-lowering therapy (LLT) after acute myocardial infarction (AMI). We analysed whether this under-prescription currently persists and has an impact on long-term outcomes. Methods results The FAST-MI programme consists of nationwide registries including all patients admitted for AMI ≤ 48 h from onset over a 1 month period in 2005, 2010, 2015, with follow-up. This analysis focused high-intensity LLT (atorvastatin ≥ 40 mg or equivalent, any combination statin ezetimibe) women men. accounted 28% (N = 3547) the 12 659 patients. At discharge, was significantly prescribed [54 vs. 68% men, P < 0.001, adjusted odds ratio (OR) 0.78(95% confidence interval (CI) 0.71–0.87)], trend that did not improve time: 25 35% (P 0.14); 66 79% 0.001); 67 79.5% 0.001). In contrast, female sex associated lack other recommended treatments at discharge: beta-blockers [adjusted OR 0.98(95% CI 0.88–1.10), 0.78], renin–angiotensin blockers 0.94(95% 0.85–1.03), 0.18]. High-intensity discharge improved 5 year survival infarct- stroke-free hazard ratios (HR) 0.74(95% 0.64–0.86), 0.001 HR: 0.81(95% CI: 0.74–0.89); respectively]. Similar were found using propensity score-matched [HR LLT: 0.82(95% 0.70–0.98), 0.03]. Conclusion suffer bias regarding prescription AMI, which attenuate between 2005 potential consequences both risk cardiovascular events.
Language: Английский
Citations
3
Medicine, Journal Year: 2024, Volume and Issue: 103(12), P. e37637 - e37637
Published: March 22, 2024
This study aimed to investigate the impact of latest guidelines on real-world clinical practice initial lipid-lowering therapy, especially use ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in China. All adult patients diagnosed with acute myocardial infarction our hospital between August 31, 2018, 2020, were divided into following 2 groups: those treated before guideline release, after release. A propensity score-matched method was used, logistic regression used assess association intensive statin, PCSK9 inhibitor usage together treatment results groups. total 325 enrolled this study, including 141 who admitted release 184 After a median follow-up time 8.20 months, mean low-density lipoprotein cholesterol 1.87 ± 0.59 mmol/L (1.87 0.55 group vs 1.88 0.62 group, P = .829). score matching, statin therapy decreased without statistical significance (17.00% 28.00%, .090), whereas increased (19.00% 8.00%, .039; 10.00% 3.00%, .085, respectively). In models, associated statistically significantly (odds ratio [OR]: 1.91; 95% confidence interval [CI]: 1.21, 3.02; .005), marginally statins (OR: 0.68; CI: 0.45, 1.03; .069) 1.31; 0.98, 1.76; .068). single-center, data analysis, 2019 European Society Cardiology/European Atherosclerosis guidelines, an increasing number recent initially receiving inhibitors.
Language: Английский
Citations
2
American Journal of Preventive Cardiology, Journal Year: 2024, Volume and Issue: 19, P. 100702 - 100702
Published: June 23, 2024
The inhibition of intestinal cholesterol absorption by ezetimibe improves outcomes after myocardial infarction (MI), yet real-world data on is scarce. We studied the usage and association with outcome MI. Consecutive MI patients in Finland (2010-2018) were retrospectively (N = 57,505; 65% men; mean age 69 years). study collected from national registries. median follow-up was 4.5 (IQR 2.8-7.1) years. Between-group differences adjusted for using multivariable regression. Ezetimibe use competing risk analyses. cumulative incidence 3.7% at 90 days, 13.4% 5 years, 19.8% 10 Younger one strongest predictors (adj.sHR 6.67; CI 5.88-7.69 aged <60 vs ≥80 Women more likely to during than men. average proportion 6.8%. (11.7% discontinued 43.6% follow-up. Patients early therapy had lower all-cause mortality (33.6% 45.1%; adj.HR 0.77; 0.69-0.86; P<0.0001). Early associated irrespective sex, age, atrial fibrillation, diabetes, heart failure, malignancy, revascularization, or statin use. Ongoing a time-dependent analysis (adj.HR 0.53; 0.48-0.59; death MI, its therapeutic limited, discontinuation frequent.
Language: Английский
Citations
2
European Heart Journal - Cardiovascular Pharmacotherapy, Journal Year: 2023, Volume and Issue: unknown
Published: Nov. 10, 2023
Using rosuvastatin, the RACING (randomized comparison of efficacy and safety lipid-lowering with statin monotherapy versus statin/ezetimibe combination for high-risk cardiovascular diseases) trial showed beneficial effects combining moderate-intensity ezetimibe compared high-intensity in patients atherosclerotic disease. This study investigated whether therapy extend to treated atorvastatin, not daily clinical practice.Using stabilized inverse probability treatment weighting, a total 31 993 who were prescribed atorvastatin after drug-eluting stent (DES) implantation identified from nationwide cohort database: 6 215 20 mg plus 10 (combination therapy) 25 778 40-80 monotherapy. The primary endpoint was 3-year composite death, myocardial infarction, coronary artery revascularization, hospitalization heart failure treatment, or non-fatal stroke accordance design. Combination associated lower incidence (12.9% vs. 15.1% monotherapy; hazard ratio [HR] 0.81, 95% confidence interval [CI] 0.74-0.88, p < 0.001). Compared monotherapy, also significantly rates discontinuation (10.0% 8.4%, HR CI 0.73-0.90, 0.001) new-onset diabetes requiring medication (8.8% 7.0%, 0.80, 0.70-0.92, = 0.002).In practice, combined approach utilizing correlated favorable outcomes, drug compliance, reduced medications DES implantation. Trial registration: ClinicalTrial.gov (NCT04715594).
Language: Английский
Citations
5
Reviews in Cardiovascular Medicine, Journal Year: 2023, Volume and Issue: 24(12), P. 350 - 350
Published: Dec. 13, 2023
Although great progress has been made in the diagnostic and treatment options for dyslipidemias, unawareness, underdiagnosis undertreatment of these disorders remain a significant global health concern. Growth digital applications newer models care provide novel tools to improve management chronic conditions such as dyslipidemia. In this review, we discuss evolving landscape lipid 21st century, current gaps possible solutions through new care. Our discussion begins with history development value-based national establishment quality metrics various conditions. These concepts on level healthcare policy not only inform reimbursements but also define standard Next, consider advances atherosclerotic cardiovascular disease risk score calculators well imaging modalities. The impact growth health, ranging from telehealth visits online platforms mobile applications, will be explored. We then evaluate ways which machine learning artificial intelligence-driven algorithms are being utilized address management. From an organizational perspective, trace redesign medical practices incorporate multidisciplinary team model care, recognizing that is multifaceted requires comprehensive approach. Finally, anticipate future dyslipidemia management, assessing many burden can reduced population-wide scale.
Language: Английский
Citations
5
Journal of the American Heart Association, Journal Year: 2023, Volume and Issue: 12(18)
Published: Sept. 6, 2023
Language: Английский
Citations
4
Journal of the American Heart Association, Journal Year: 2024, Volume and Issue: 13(1)
Published: Jan. 2, 2024
It has been 1 year since I officially began my term as Editor-in-Chief of the Journal American Heart Association (JAHA).When back then, laid out our plans and priorities. Along with JAHA editors staff, it gratifying to think through follow execution those goals, aimed at enhancing experiences contributors, reviewers, readers alike.We met, we talked, listened, learned, refined, implemented.On this note, present a brief overview major accomplishments in 2023 key aspirations for 2024, well announce annual list individuals groups who greatly contributed advancing journal's mission assist science, scientist, society creating world longer, healthier lives. YEAR IN REVIEWOverall, number article submissions slightly increased from 2022, driven by rise original research submissions, especially outside United States.We publishing new types including study protocol articles, patient/caregiver editorials, an introduction (AHA) president.We published 5 starting on screening cardiac amyloidosis minority populations, 2 editorials perspective that looked challenges caregivers survivors in-hospital care face, 3 covered impressive career journey AHA president, Dr Joseph Wu. 4 We launched initiatives revamped previous one.First, podcast titled Aha!With JAHA, interviewed authors select articles involved important policymaking around cardiovascular cerebrovascular health (https:// www.ahajo urnals.org/ jaha/ podcast).A total 8 episodes were recorded, special one accompanying video youtu.be/ Q20a7 aqZeV4?si= ZKQK2 h-LN17d rX2L), Distinguished Hearts Minds Roundtable, which featured insightful discussions 6 Scientists, during honorees talked about their discoveries, envisioned future areas, shared tips achieving successful scientific careers.Second, inaugural Symposium Scientific Sessions, Moving Towards Social Justice Cardiovascular Health: A Session, took place November 12, comprised presentations social determinants equitable health, interventions bridge equity gaps, approaches increase inclusion women racial ethnic minorities clinical trials, avenues enhance workforce diversity.Third, modified early editorial board curriculum include more opportunities reviewing handling exposure mentoring seasoned editors.
Language: Английский
Citations
1
European Heart Journal Open, Journal Year: 2024, Volume and Issue: 4(2)
Published: March 1, 2024
The retrospective NEPTUNO study evaluated the effectiveness of Centro Nacional de Investigaciones Cardiovasculares (CNIC)-polypill (including acetylsalicylic acid, ramipril, and atorvastatin) vs. other therapeutic approaches in secondary prevention for cardiovascular (CV) disease. In this substudy, focus was on subgroup patients with ischaemic heart disease (IHD).
Language: Английский
Citations
1